Patients with EGFR-mutated NSCLC who have progressed after multiple lines of therapy may have meaningful and durable responses to a novel antibody-drug conjugate HER3-DXd, new phase 2 data suggest.
US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Startup Star Therapeutics will use the Series B funding to support clinical development of a drug candidate for von Willebrand disease, a bleeding disorder. The capital will also support the formation of new biotech subsidiaries developing antibodies with therapeutic applications in hematology and immunology.